• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Poll: Do you believe biosimilars have the same efficacy as branded medications?

Poll

Weigh in on this month's survey question. The poll will be open until December 16, 2022.

Do you believe biosimilars have the same efficacy as branded medications?

Yes
No
Unsure
Related Videos
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
Related Content
Prior intravitreal injections may be associated with risk of postoperative cataract surgery complications

Prior intravitreal injections may be associated with risk of postoperative cataract surgery complications

Article
Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures

(EyePod) From idea to impact: Navigating ophthalmic innovation

Podcast
Study finds tylectomy, paired with normal therapy, shows positive impact on eye survival in retinoblastoma patients

Study finds tylectomy, paired with normal therapy, shows positive impact on eye survival in retinoblastoma patients

Article
Eyepod: Ocugen CEO gives update on OCU400

Eyepod: Ocugen CEO gives update on OCU400

Podcast
Interactive online tool, Vision Simulator, highlights vision loss caused by retinal diseases

Interactive online tool, Vision Simulator, highlights vision loss caused by retinal diseases

Article
SalioGen Therapeutics taps development candidate for ABCA4-mediated Stargardt disease

SalioGen Therapeutics taps development candidate for ABCA4-mediated Stargardt disease

Article
© 2024 MJH Life Sciences

All rights reserved.